Kleinjung, Tobias
Peter, Nicole
Schecklmann, Martin
Langguth, Berthold http://orcid.org/0000-0002-7066-510X
Funding for this research was provided by:
Universität Regensburg
Article History
Received: 28 December 2023
Accepted: 31 July 2024
First Online: 13 August 2024
Declarations
:
: T. Kleinjung received honoraria for consultancy and speaker’s fees from Sonova and Schwabe and travel and accommodation payments from Cochlear. His research was funded from the Tinnitus Research Initiative, the Swiss National Science Foundation, the European Union, the Zurich Hearing Foundation, and Cochlear. N. Peter received travel and accommodation payments from Cochlear. Her research is funded from the Zurich Hearing Foundation. M. Schecklmann received honoraria for consultancy, reports, and speakers’ fees from Aureliym, MAG & More, Medical Tribune, Neuromod, and Schwabe; research funding from the Tinnitus Research Initiative, the German Research Foundation, the German Bundesministerium für Bildung und Forschung, the American Tinnitus Association, Neuromod, and the European Union; and funding for equipment from MagVenture, MAG & More, NeuroCare, and Deymed Diagnostic. B. Langguth received honoraria for consultancy and speakers’ fees from ANM, AstraZeneca, Autifony Therapeutics, Decibel Therapeutics, Desyncra, Gerson Lehrman Group, Lundbeck, Merz, MagVenture, Medical Tribune, Neurolite, Neuromod, Novartis, Pfizer, Rovi, Schwabe, Sea Pharma, Servier, Sonova, and Sound Therapeutics; research funding from the Tinnitus Research Initiative, Bayhost, the German Research Foundation, the German Bundesministerium für Bildung und Forschung, the American Tinnitus Association, AstraZeneca, cerbomed, Neuromod, and the European Union; funding for equipment from MagVenture and Deymed Diagnostic; and travel and accommodation payments from Eli Lilly, Lundbeck, Servier, and Pfizer. He owns shares of Sea Pharma.